Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $57
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.
Wells Fargo analyst Eva Fortea Verdejo maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $53 to $57.